Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
Experimental drugs have extremely limited human consumption data. There is not enough reliable information about this substance. This is most likely because the substance is is not very old. Information on these substances is limite and incomplete. Please be cautioned. Always practice harm reduction.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
- 1H-Indol-4-ol, 3-[2
-(dimethylamino)eth[ACD/Index Name] yl]-
)ethyl]-1H-indol-4-[ACD/IUPAC Name] ol
)ethyl]-1H-indol-4-[German][ACD/IUPAC Name] ol
)éthyl]-1H-indol-4-[French][ACD/IUPAC Name] ol
- 4-hydroxy DMT
thyl)-4-hydroxyindo le, N,N-Dimethyl-4- hydroxytryptamine
- 5-22-12-00014 (Beil
stein Handbook Refe[Beilstein] rence)
- CX 59
- EINECS 208-296-5
- Indol-4-ol, 3-(2-(d
- Indol-4-ol, 3-[2-(d
- NM 2625000
Psilocin is a substutued tryptamine alkaloid, that is present in most psychedelic mushrooms. It is relatively unstable in solution due to the -OH group.
Psilocin is the primary psychoactive constituent in certain species of mushrooms, and as a closely related structural analog of the powerful visionary entheogen DMT (also known as N,N-dimethyltryptamine). Psilocin was first isolated and named by Albert Hofmann in 1958. Its psychoactivity is thought to emerge from the close chemical similarities with the neurotransmitter serotonin, which enables it to interact with a range of serotonin receptor sites throughout the brain that are integral for sensory and cognitive processes.
Notably, while psilocin naturally co-occurs with psilocybin in significant amounts of most psilocybin-containing mushrooms, it is only ever rarely encountered in its synthetic form. Anecdotal reports describe pure psilocin as a more lucid and aggressive version of psilocybin mushrooms. Unlike other highly prohibited substances, psilocin is not considered to be addictive or physiologically toxic.
Nevertheless, adverse psychological reactions such as severe anxiety, paranoia and psychosis are always possible, particularly among those predisposed to mental illness. It is highly advised to use harm reduction practices if using this substance.
You can help by expanding it.
Psilocin and its phosphorylated inactive precursor (i.e. prodrug) psilocybin were first isolated and named in 1958 by Swiss chemist Albert Hofmann. Hofmann obtained the chemicals from laboratory-grown specimens of the entheogenic mushroom Psilocybe mexicana before proceeding to find their synthetic routes.
Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain.
4-HO-DMT is substituted at R4 of its indole heterocycle with an hydroxyl (-OH) functional group; it also contains two methyl groups CH3- bound to the terminal amine RN of the ethyl side chain.
This makes psilocin the 4-hydroxy structural analog of DMT, and dephosphorylated analog of psilocybin. Psilocin can be obtained by dephosphorylation of natural psilocybin under strongly acidic or under alkaline conditions via hydrolysis, which is how it becomes metabolically active in the human body as well. In terms of its physical properties, 4-HO-DMT is relatively unstable in solution due to its phenolic hydroxy (-OH) group.
In the presence of oxygen it readily forms bluish and dark black degradation products.
For this reason it is recommended to store it in optimal chemical storage conditions (i.e.
cool, dry, away from light) to avoid excessive degradation.
|Avg. Mass||204.2682 Da|
|Monoisotopic Mass||204.126266 Da|
Interactions and Synergies
There are no existing interaction or synergy data for this drug.
|Marguis Test Result|
Psilocin’s psychedelic effects are believed to come from its interactions at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation. In contrast to LSD, this compound has no significant effect on dopamine receptors and only affects the noradrenergic system at very high dosages.
Anecdotal reports characterize the effects of psilocin as powerful and visionary, with a deep, all-encompassing headspace, immersive visuals with high-level geometry, and a rapid challenging come up that is both reportedly more lucid and anxiety-provoking than orally ingested psilocybin mushrooms; this may make the experience overly intense for those who are not experienced with psychedelics.
- Sedation - In terms of its effects on the physical energy levels of the tripper, psilocin is considered by most to be relaxing, stoning and mildly sedating. This sense of sedation is often accompanied by compulsive yawning.
- Perception of bodily heaviness - This effect corresponds with the general sense of sedation and relaxation that characterizes psilocin experiences, this manifests as a bodily heaviness that discourages movement but is typically only prominent during the first half of the trip. This particular physical effect seems to be more commonly experienced and pronounced with certain “woodlover” species of mushrooms such as Psilocybe azurescens.
- Spontaneous physical sensations - The "body high" of psilocin can be described as a pleasurable, soft and all-encompassing tingling sensation or glow. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached. Once the peak of the experience or sensation is reached it can feel incredibly euphoric and tranquil or heavy and immobilizing depending on the dose.
- Changes in felt bodily form - This effect is often accompanied by a sense of warmth or unity and usually occurs around the peak of the experience or directly after. Users can feel as if they are physically part of or conjoined with other objects. This is usually reported as feeling comfortable in its sensations and even peaceful.
- Tactile enhancement - This effect is less prominent than with that of LSD or 2C-B but is still present and unique in its character. It is repeatedly described as feeling very primitive in its nature often times with the small hairs on the users arms or legs feeling slightly itchy or even ticklish against the skin.
- Changes in felt gravity
- Nausea - This effect can be greatly lessened or even completely avoided if the individual has an empty stomach prior to ingestion. It is often recommended that one either refrain from eating for approximately 6 to 8 hours beforehand, or eat a light meal 3 to 4 hours before if they are feeling physically fatigued. In the rare circumstances that pure psilocin is ingested this effect is considered to be much less prominent than it is with psilocybin mushrooms.
- Excessive yawning - This effect seems to be uniquely pronounced among psilocin and related tryptamines. It can occur to a lesser degree on LSD and very rarely on psychedelic phenethylamines like mescaline. It typically occurs in combination with watery eyes.
- Brain zaps - Although this effect is very rare, it can still occur for those susceptible to it. This component is however much less common and intense than it is with serotonin releasing agents such as MDMA.
- Watery eyes
- Muscle contractions
- Olfactory hallucination
- Frequent urination
- Pupil dilation
- Runny nose
- Increased salivation
- Seizure - This is a rare effect but can happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, undernourished, or fatigued.
The cognitive effects of psilocin are described by many as extremely relaxing, profound and stoning in style when compared to other commonly used psychedelics such as LSD or 2C-B which tend to be energetic and stimulating, it is also regarded as being notably more lucid than psilocybin mushrooms but not as clearheaded as DMT. It contains a large number of both typical and unique psychedelic cognitive effects. The most prominent of these typical effects generally include:
- Enhancement and suppression cycles - This can be described as constant waves of extremely stimulated and profound thinking which are spontaneously surpassed in a cyclic fashion by waves of general thought suppression and mental intoxication. These two states seem to switch between each other in a consistent loop once every 20 to 60 minutes.
- Emotionality enhancement - This effect can be described as being more prominent, consistent and profound when compared to other traditional psychedelics such as mescaline or LSD. This can lead to strong feelings of compassion, urgency and even completely sporadic moments of intense emotional significance that can also be periodically affected by enhancement and suppression cycles.
- Empathy, affection, and sociability enhancement - This effect differs from MDMA and other entactogens in that it isn't as central to the experience, feels less forced and more natural and is experienced at a less consistent rate. The sociability enhancement in particular only occurs rarely and it appears to be more emotional.
- Simultaneous emotions
- Language suppression - This effect can be described as a perceived inability or general unwillingness to talk aloud despite feeling perfectly capable of formulating coherent thoughts within one's internal narrative. It is much more common among inexperienced users.
- Autonomous voice communication
- Cognitive euphoria
- Analysis enhancement - This effect is consistent in its manifestation and outrospection dominant.
- Conceptual thinking
- Personal bias suppression
- Novelty enhancement
- Immersion enhancement
- Creativity enhancement
- Feelings of impending doom - This effect is usually only experienced during the come up phase but typically completely passes or subsides once the primary effects begin. It should be noted that this effect is relatively consistent and normal for psilocin and related tryptamines which is why a positive and well-informed mindset is key. Less regularly this aspect can also occur during the peak but will most often be met after with sensations of euphoria or rejuvenation.
- Catharsis - While this component can occur spontaneously, it typically follows a difficult phase of the experience, if not the entirety of the experience itself.
- Rejuvenation- While this component can occur spontaneously at any point, it typically follows a difficult phase of the experience, if not the entire experience itself. It is however almost always felt during the offset of a psilocin trip and tends to slowly transition into the after effects which are generally described as positive. These positive or mindful after effects are sometimes referred to as an "afterglow" and is both common and consistent for psilocin and related tryptamines.
- Memory suppression
- Addiction suppression
- Thought connectivity
- Thought deceleration
- Thought organization
- Confusion - This effect is commonly reported to occur at a higher rate than with other psychedelics such as LSD or mescaline. It is more commonly observed in users who are generally inexperienced with psychedelics.
- Déjà vu
- Increased music appreciation
- Increased sense of humor
- Ego replacement - Although this effect is rare and more likely to occur with certain psychedelics like DMT or ayahuasca, it can still occur with high dosages.
- Personality regression - While this effect is not typically observed, it can still spontaneously manifest and is thought to depend primarily on the user's set and setting.
- Time distortion
- Colour enhancement - In comparison to other psychedelics, this effect may appear to be more saturated.
- Visual acuity enhancement - This effect typically occurs at lower to medium doses and becomes increasingly suppressed at higher doses.
- Pattern recognition enhancement
- Drifting (melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as highly detailed, realistic, slow and smooth in motion and static in appearance.
- Colour shifting
- Colour tinting
- Visual haze
- After images
- Symmetrical texture repetition
- Perspective distortions
- Depth perception distortions
- Environmental orbism
- Scenery slicing
- Environmental patterning
The visual geometry present on this substance can be described as more similar in appearance to that of 4-AcO-DMT, ayahuasca and 2C-E than LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, structured in organization, brightly lit, and multicoloured in scheme, glossy in shading, soft in its edges, large in size, slow in speed, smooth in motion, rounded in its corners, non-immersive in-depth and consistent in intensity. It has a very "organic" feel and at higher dosages is significantly more likely to result in states of Level 8B visual geometry over level 8A.
Psilocin and its various other forms produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. These effects generally include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical, or transcendental nature in their overall theme.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - These are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- Shadow people
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
- Dosage independent intensity
Psilocin is a Schedule I drug under the Convention on Psychotropic Substances, meaning the possession and sale of it (including psilocin and psilocybin-containing mushrooms) is prohibited in most countries.
- Lüscher, C., & Ungless, M. A. (2006). The Mechanistic Classification of Addictive Drugs, 3(11). https://doi.org/10.1371/journal.pmed.0030437
- Nichols, D. E. (2016). "Psychedelics." Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478
- Strassman, R. J. (1984). Adverse Reactions to Psychedelic Drugs: A Review of the Literature. The Journal of Nervous and Mental Disease, 172(10), 577-595. PMID: 6384428
- Hofmann, A., Heim, R., Brack, A., Kobel, H., Frey, A., Ott, H., Petrzilka, Th. and Troxler, F. (1959), Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. HCA, 42: 1557–1572. https://doi.org/10.1002/hlca.19590420518
- Petri, G., Expert, P., Turkheimer, F., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks, 14–18. https://doi.org/10.1098/rsif.2014.0873
- Psilocybin Investigator’s Brochure | http://www.maps.org/research-archive/psilo/psilo_ib.pdf
- Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. https://doi.org/10.1177/0269881114548296
- Armstrong, B. D., Paik, E., Chhith, S., Lelievre, V., Waschek, J. A., & Howard, S. G. (2004). Potentiation of (DL)‐3, 4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939. Neuroscience Research Communications, 35(2), 83-95. https://doi.org/10.1002/nrc.20023
- Potentiation of MDMA-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists | https://indiana.pure.elsevier.com/en/publications/potentiation-of-34-methylenedioxymethamphetamine-induced-dopamine
- Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. | https://www.ncbi.nlm.nih.gov/pubmed/17572501
- Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71-78. https://doi.org/10.1001/archgenpsychiatry.2010.116
- Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Taylor, D. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30065
- Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., ... & Hobden, P. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143. https://doi.org/10.1073/pnas.1119598109
- Farb, N. A. S., Anderson, A. K., Bloch, R. T., & Segal, Z. V. (2011). Mood Linked Responses in Medial Prefrontal Cortex Predict Relapse in Patients with Recurrent Unipolar Depression. Biological Psychiatry, 70(4), 366–372. https://doi.org/10.1016/j.biopsych.2011.03.009
- Bhagwagar, Z., Hinz, R., Taylor, M., Fancy, S., Cowen, P., & Grasby, P. (2006). Increased 5-HT 2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11 C] MDL 100,907. American Journal of Psychiatry, 163(9), 1580-1587. http://dx.doi.org/10.1176/ajp.2006.163.9.1580
- Meyer, J. H., McMain, S., Kennedy, S. H., Korman, L., Brown, G. M., DaSilva, J. N., ... & Houle, S. (2003). Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. American Journal of Psychiatry, 160(1), 90-99. https://www.doi.org/10.1176/appi.ajp.160.1.90
- "Green list" (PDF). INCB. Retrieved 2017-10-11.
- Controlled Drugs and Substances Act of Canada
- "Vierte Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (I saraksts) | http://likumi.lv/doc.php?id=121086
- Legislation - Drugs Act 2005| http://www.legislation.gov.uk/ukpga/2005/17/contents
- FDA - Controlled Substances Act| http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htm
- 1717 CheMall HE005333
- 1717 CheMall HE348021
- A&J Pharmtech AJ-143348
- ACToR: Aggregated Computational Toxicology Resource 520-53-6
- Advanced Technology & Industrial 3539063
- AKos AKOS022505992
- American Custom Chemicals Corp API0015023
- American Custom Chemicals Corp PXT0001714
- American Custom Chemicals Corp PXT0002129
- American Custom Chemicals Corp RDL0008111
- ApexBio B5583
- Aurora Fine Chemicals A02.559.183
- Aurora Fine Chemicals K02.114.844
- BindingDB 50081701
- Biosynth P-7800
- Biosynth Carbosynth FP27258
- Cayman Chemical 11864
- Cayman Chemical 11864.0
- Cayman Chemical 15696
- Cayman Chemical 15696.0
- ChEBI CHEBI:8613
- ChEMBL CHEMBL65547
- ChemDB 3968309
- ChemIDplus 000520536
- ChemIDplus 520536
- Chemspace CSC000178430
- Collaborative Drug Discovery 41500
- DiscoveryGate 4980
- DSigDB d4ttd_10378
- eMolecules 593357
- EPA DSSTox DTXCID5028825
- FDA UNII - NLM CMS88KUW0G
- FDA UNII - NLM UNII: CMS88KUW0G
- Finetech Industry FT-0674147
- Glentham Life Sciences GP1958
- Human Metabolome Database HMDB0042000
- Human Metabolome Database HMDB42000
- iChemical EBD71183
- Jean-Claude Bradley Open Melting Point Dataset 21589
- Journal of Heterocyclic Chemistry 19810175_12A
- KEGG C08312
- LabNetwork LN01303176
- Laboratory Chemical Safety Summary 4980
- LeadScope LS-83676
- MassBank JP003736
- MuseChem I010951
- Natural Product Updates NPU1101059222
- NIST Chemistry WebBook 3519396488
- NIST Spectra mainlib_247861
- NIST Spectra nist ri
- NIST Spectra replib_250577
- NIST Spectra replib_313177
- NIST Spectra replib_335391
- NMRShiftDB 20191658
- NPAtlas NPA009691
- PubChem 4980
- PubMed 10077856
- PubMed 100806
- PubMed 10510769
- PubMed 10514296
- PubMed 10572973
- PubMed 1063421
- PubMed 10774258
- PubMed 10978653
- PubMed 10978655
- PubMed 11061684
- PubMed 11092582
- PubMed 11101361
- PubMed 11104939
- PubMed 11373000
- PubMed 116288
- PubMed 11824592
- PubMed 11897967
- PubMed 11962085
- PubMed 12191719
- PubMed 12356281
- PubMed 12749196
- PubMed 13652944
- PubMed 13715851
- PubMed 13715852
- PubMed 13859403
- PubMed 13867140
- PubMed 14007905
- PubMed 14008293
- PubMed 14015664
- PubMed 14453239
- PubMed 14581081
- PubMed 14631713
- PubMed 14642723
- PubMed 15036436
- PubMed 1548895
- PubMed 15526212
- PubMed 15813544
- PubMed 16018591
- PubMed 16061378
- PubMed 16401965
- PubMed 16423222
- PubMed 17002211
- PubMed 17159796
- PubMed 17221430
- PubMed 17340315
- PubMed 17340325
- PubMed 17342589
- PubMed 17618679
- PubMed 17688928
- PubMed 17907620
- PubMed 17988464
- PubMed 2094720
- PubMed 238721
- PubMed 272982
- PubMed 3006088
- PubMed 30911
- PubMed 3430170
- PubMed 3631327
- PubMed 3952123
- PubMed 4038992
- PubMed 4040953
- PubMed 4788158
- PubMed 4800137
- PubMed 481115
- PubMed 556766
- PubMed 559753
- PubMed 560306
- PubMed 5641719
- PubMed 5922147
- PubMed 600026
- PubMed 6109775
- PubMed 6114779
- PubMed 6259355
- PubMed 6694110
- PubMed 6805022
- PubMed 7194879
- PubMed 7201053
- PubMed 7201054
- PubMed 731434
- PubMed 8207663
- PubMed 8246528
- PubMed 882579
- PubMed 9511859
- PubMed 9657222
- Sabio-RK 10411
- Santa Cruz Biotechnology sc-219670
- Sigma-Aldrich CERILLIAN-P-098
- Sigma-Aldrich SIAL-P4054
- Sigma-Aldrich SIGMA-P2279
- Springer Nature A characteristic effect of hallucinogens on investigatory responding in rats
- Springer Nature A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 ??-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches
- Springer Nature A validated method for quantitation of psilocin in plasma by LCu2013MS/MS and study of stability
- Springer Nature Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study
- Springer Nature Autoradiographic studies on the distribution of psychoactive drugs in the rat brain
- Springer Nature Bestimmung von Nicotins??ure und Nicotins??ureamid in pharmazeutischen Pr??paraten
- Springer Nature Chromosomendefekte bei Psilocybin-Patienten
- Springer Nature Comparison of psilocin with psilocybin, mescaline and LSD-25
- Springer Nature Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS
- Springer Nature Development of a psilocin immunoassay for serum and blood samples
- Springer Nature Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a u201cmagic mushroomu201d user
- Springer Nature Effects of mescaline and psilocin on acquisition, consolidation, and performance of light-dark discrimination in two inbred strains of mice
- Springer Nature High-affinity 3H-serotonin binding to caudate: Inhibition by hallucinogens and serotoninergic drugs
- Springer Nature Honey with Psilocybe mushrooms: a revival of a very old preparation on the drug market?
- Springer Nature Identifizierung von Psilocin
- Springer Nature Indolealkylamines: Biotransformations and Potential Drugu2013Drug Interactions
- Springer Nature Induction of multipolar spindles by single X-irradiated sperm
- Springer Nature Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan
- Springer Nature Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
- Springer Nature Pharmacological actions of 4-hydroxytryptamine and 4-hydroxytryptophan
- Springer Nature Platinbromwasserstoffs??ure, H2PtBr6 als neues Reagens f??r den mikrochemischen Nachweis von organischen Basen und Alkaloiden
- Springer Nature Psilocybin as a discriminative stimulus: Lack of specificity in an animal behavior model for u2018hallucinogensu2019
- Springer Nature Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing?study on P300 and mismatch negativity in healthy volunteers
- Springer Nature Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim
- Springer Nature Psychoactive tryptamines from basidiomycetes
- Springer Nature Pyrazincarbons??ureamid
- Springer Nature Researches on imidazole derivatives XL. Synthesis of benzimidazole derivatives of psilocine
- Springer Nature Screening hallucinogenic drugs
- Springer Nature Severe aggression in rats induced by mescaline but not other hallucinogens
- Springer Nature Temperatur als wesentlicher Parameter f??r die Gr??ssenabh??ngigkeit von Lebensvorg??ngen
- Springer Nature The action of tryptamine on the dog spinal cord and its relationship to the agonistic actions of LSD-like psychotogens
- Springer Nature The fate of 4-hydroxytryptophan in the rat organism
- Springer Nature The hallucinogenic world of tryptamines: an updated review
- Springer Nature Zur Identifizierung von Psilocin, einem psychotropen Inhaltstoff mexikanischer Rauschpilze der Gattungen Psilocybe und Stropharia
- The Merck Index Online cs000000015556
- Thieme Chemistry 10.1055/s-0028-1087386
- Thomson Pharma 00058470
- Tocris Bioscience 4412
- Toxin, Toxin-Target Database T3D2458
- Wikidata Q409150
- Wikipedia Psilocin
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.